Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mucus-Busting asthma trial fizzles out

NCT ID NCT03822637

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small study tested whether adding n-acetylcysteine (NAC) to albuterol could improve lung function and reduce mucus plugs in people with moderate-to-severe asthma. Only 4 participants were enrolled before the trial was terminated early. The crossover design gave each person two weeks of NAC plus albuterol and two weeks of placebo plus albuterol, but the tiny size means no firm conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
n-acetylcysteine (NAC) plus albuterol
What this could lead to
If it works, this could point toward a way to clear mucus plugs in the airways and improve breathing for people with moderate-to-severe asthma.
What could go wrong
The trial was terminated early and enrolled only 4 people, so results are very limited. It is unclear if NAC provides any real benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

4 people

The number who actually took part.

Started

Feb 2019

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female between the ages of 18 and 80 years of age at Visit 1 2. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. 3. Able to perform reproducible spirometry according to American Thoracic Society (ATS) criteria 4. Physiological evidence of airflow obstruction (FEV1 bronchodilator reversibility of ≥ 12% or hyperreactivity to methacholine reflected by a methacholine provocative concentration that results in a 20% fall in FEV1(PC20) ≤ 16 mg/mL) 5. Clinical history of asthma per patient report or medical record 6. Pre-bronchodilator FEV1 \> 35% predicted 7. Post-bronchodilator FEV1 \> 40% but \< 90% predicted 8. Asthma requiring treatment with inhaled corticosteroids (ICS) for 3 months or greater 9. CT mucus score ≥ 5 10. Ability to tolerate study drug reflected by a post-treatment FEV1 ≥ 80% of pre- treatment, pre-bronchodilator FEV1 Exclusion Criteria: 1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data 3. Smoking of tobacco or other recreational inhalants in last year and/or \>10 pack-year smoking history 4. Adherence to study drug ≤ 70% after first treatment period 5. Current participation in an investigational drug trial 6. Other chronic pulmonary disorders, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways 7. Unwillingness to follow study procedures 8. History of allergy or intolerance to study drug 9. Any other criteria that places the subject at unnecessary risk according to the judgment of the Principal Investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UCSF Airway Clinical Research Center

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.